EdisonNTanMD

Geriatric Medicine, Hospital Medicine/Hospitalist, Healthcare Research and Healthcare Policy, Medical Information Sciences

Florida Medical Center Outpatient Center Morton Plant Meases Hospitalist HCR Medical Director Principal Investigator of Clinical Trials

Join to view full profile

Dr. Tan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tan's full profile

Already have an account?

Office
1840 N Highland Ave
Clearwater, FL 33755
Phone+1 727-442-3001

Fax+1 727-467-9106

Summary

Edison Tan, MD, is a healthcare provider based in Clearwater, FL. His specialty is Internal Medicine, with sub-specialties in Geriatric Medicine, Hospital Medicine/Hospitalist, Healthcare Research and Healthcare Policy, and Medical Information Sciences. Dr. Tan completed his residency in 1998 and internship in 1995-1996, both at Cook County Health and Hospitals System, after graduating from Far Eastern University Nicanor Reyes Medical Foundation in 1993. He currently holds a number of positions, including Clinical Faculty at Orlando College of Oste and Medical Advisor for the State of Florida and Florida's 12th Congressional District. He has expertise in metabolic syndrome, bariatric medicine, diabetes mellitus, hospitalist medicine, and hyperlipidemia. Aside from his numerous medical publications, Dr. Tan has participated in various clinical trials and received a CMS Meaningful Use Stage 1 Certification from eClinicalWorks EHR.

Education & Training

Cook County Health and Hospitals SystemResidency, Internal Medicine, 1998
Cook County Health and Hospitals SystemInternship, Internal Medicine, 1995 - 1996
Far Eastern University Nicanor Reyes Medical FoundationClass of 1993

Certifications & Licensure

FL State Medical License 1999 - 2026
IL State Medical License 1995 - 2011
MI State Medical License 1998 - 2002
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013

Clinical Trials

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure Start of enrollment: 2006 Mar 01
Completed
Phase 3
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Start of enrollment: 2006 Oct 04
Completed
Phase 4
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults Start of enrollment: 2021 Jan 28
Completed
Phase 3
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults Start of enrollment: 2020 Dec 02
Completed
Phase 3
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. Start of enrollment: 2020 Nov 21
Completed
Phase 3
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years Start of enrollment: 2021 Jun 30
Recruiting
Phase 3
Reparixin in COVID-19 Pneumonia - Efficacy and Safety Start of enrollment: 2020 May 05
Terminated
Phase 2, Phase 3
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Start of enrollment: 2022 Apr 06
Recruiting
Phase 3
Join now to see all

Publications & Presentations

Journal Articles

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Myron J. Levin, M.D, nejm, 4/20/2022
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)
Steven E. Nissen, MD, MACC, NEJM, 4/12/2016
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure
Barry H Greenberg 1, Mandeep Mehra, John R Teerlink, Paul Ordronneau, David McCollum, Edward M Gilbert, American Journal of Cardiology, 10/2/2006

Abstracts/Posters

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
Aztra Zeneca, Press Release, Global, 11/16/2021
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
Adrian Kemp Astra Zeneca, Press Release, Global, 8/20/2021

Lectures

COVID: An update
Clearwater, Fl - 12/6/2022

Committees

CME, Baycare Healthcare System 2018 - Present

Research History

Principal StudyA Phase III Multi-center, Open-label Sub-study in Adults to Assess the Safety, PK, and Immunogenicity of Repeat Doses of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061)
Principal InvestigatorProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Principal InvestigatorA Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
Principal InvestigatorEvusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study

Professional Memberships

American Medical Association - AMA
Member
American College of Physicians - ACP
Member
American Medical Directors Association - AMDA
Member

Other Languages

Filipino

Industry Relationships

Speaker, Daiichi Sankyo2000 - 2000